# Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Source: https://onco.cc/trials/nct06617169/  
OnCo record `nct06617169` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MNPR-101 run by Monopar Therapeutics, active and no longer recruiting.

## Summary

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors is a phase 1 interventional study registered as NCT06617169 by Monopar Therapeutics, with 12 participants planned, started 2024-10-08. Conditions recorded: Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer and Pancreatic Cancer. Interventions recorded: MNPR-101-PCTA-177Lu.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06617169
- Phase: 1
- Setting: Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers
- Sponsor: Monopar Therapeutics
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06617169: https://clinicaltrials.gov/study/NCT06617169

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [MNPR-101](https://onco.cc/drugs/mnpr-101/)
- companies: [Monopar Therapeutics](https://onco.cc/companies/monopar/)

---
JSON: https://onco.cc/api/v1/entities/nct06617169.json